Studies on adjuvant chemotherapies with mitomycin C, 5-fluorouracil and tegafur for colorectal cancer.

概要

論文の詳細を見る
In two prospective randomized studies, the effectiveness of adjuvant chemotherapy with mitomycin C (MMC), 5-fluorouracil (5-FU) and tegafur (FT) after surgical resection of colorectal carcinoma was evaluated. 1) 130 patients with colon cancer, who underwent macroscopically curative resection, were devided into two groups. In colon group A, chemotherapy consisted of intraluminal administration of MMC (50mg/100 ml saline) during operation, followed by oral or intrarectal administration of FT (600-1, 000 mg/day for a year). In colon group B, 5-FU (1, 500 mg/100 ml saline) was administrated intraluminally during operation and others were the same with colon group A. No serious adverse effects were observed in each groups. There was no significant differences in both five year survival rate and recurrence rate between two groups. 2) 158 patients with rectal cancer, who underwent macroscopically curative resection, were also devided into two groups. In rectum group A, chemotherapy consisted of intraoperative intraarterial (inferior mesenteric artery) and postoperative intravenous intermittent administration of MMC (10-4 mg/body/a injection), followed by oral administration of FT (600-800 mg/day for a year). In rectum group B, chemotherapy consisted of postoperative intravenous administration of 5-FU (250 mg/body/day for two weeks ), followed by oral administration of FT (600-800 mg/day for a year). No serious adverse effects were observed in both groups. The five year servival rate was better in group B than in group A, but the difference did not reach statistical significance (p=0.056). In patients with rectal cancer at Dukes class C, five year survial rate was significantly higher in group B than in group A (p=0.047).
日本大腸肛門病学会の論文

Studies on adjuvant chemotherapies with mitomycin C, 5-fluorouracil and tegafur for colorectal cancer.

スポンサーリンク

概要

著者

関連論文

スポンサーリンク